Drug Profile
Clemizole - Epygenix Therapeutics/University of California at San Fransisco
Alternative Names: EPX 100Latest Information Update: 07 Sep 2022
Price :
$50
*
At a glance
- Originator University of California at San Francisco
- Developer Epygenix Therapeutics
- Class Antiallergics; Antiepileptic drugs; Antihistamines; Benzimidazoles; Pyrrolidines; Small molecules
- Mechanism of Action Hepatitis C virus NS4 protein inhibitors; Histamine H1 receptor antagonists; Serotonin receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Dravet syndrome; Lennox-Gastaut syndrome
- Phase I Epilepsy
Most Recent Events
- 07 Sep 2022 Phase-I clinical trials in Epilepsy in USA (PO) prior to September 2022 (Epygenix Therapeutics pipeline, September 2022)
- 07 Sep 2022 Phase-II clinical trials in Lennox-Gastaut syndrome in USA (PO) (Epygenix Therapeutics pipeline, September 2022)
- 07 Sep 2022 Clemizole - Epygenix Therapeutics/University of California at San Fransisco receives Orphan Drug status for Epilepsy in USA